Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months

Ishii, Koji; Takamura, Naoko; Shinohara, Mie; Wakui, Noritaka; Shin, Hirokazu; Sumino, Yasukiyo; Ohmoto, Yasukazu; Teraguchi, Susumu; Yamauchi, Koji

doi:10.1016/s1386-6346(02)00279-6

Cited by 61 publications

(57 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma 8-isoprostane levels are significantly decreased in CHC patients treated with bovine Lf, indicating suppressed oxidative stress and better responsiveness to antiviral therapy (Konishi et al, 2006). Ishii et al (2003) reported that oral bovine Lf supplementation of CHC patients for up to 3 months stimulated serum interleukin-18 expression, and produced a T-helper 1 cytokine-dominant environment in the circulation, thus facilitating the effects of interferon treatment.…”

Section: Discussionmentioning

confidence: 99%

“…For example, bovine Lf was shown to inhibit HCV infection in PH5CH8 cells (Ikeda et al, 1998(Ikeda et al, , 2000 and viraemia in chronic hepatitis C (CHC) patients (Iwasa et al, 2002;Tanaka et al, 1999), whilst oral supplementation of chronic HCV patients with bovine Lf enhanced the sustained virological response to interferon (Kaito et al, 2007). In contrast, clinical trials adding Lf to the standard interferon/ribavirin therapy resulted in divergent outcomes (Hirashima et al, 2004;Ishibashi et al, 2005;Ishii et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inhibitory effects of native and recombinant full-length camel lactoferrin and its N and C lobes on hepatitis C virus infection of Huh7.5 cells

Liao

El-Fakkarany

Lönnerdal

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

Lactoferrin has been suggested to have antiviral activity against hepatitis C virus (HCV). The objective of this study was to compare the effects of recombinant camel lactoferrin (rcLf), native camel lactoferrin (ncLf) and their N and C fragments on HCV infection in Huh7.5 cells. ncLf was purified from camel milk and N and C lobes were generated proteolytically. rcLf and its fragments were synthesized using a Bac-to-Bac baculovirus expression system. All proteins except the C lobe of rcLf were soluble. The inhibitory effects on HCV entry into Huh7.5 cells were evaluated by incubation of HCV with Lf prior to infection or pre-treatment of the cells with Lf prior to infection. The inhibitory effect on HCV amplification in Huh7.5 cells was determined by Lf treatment of HCV-infected cells. Nested RT-PCR was performed to amplify intracellular HCV 59 non-coding RNA sequences. rcLf and ncLf and their fragments could prevent HCV entry into Huh7.5 cells by direct interaction with the virus and inhibited virus amplification in Huh7.5 cells. Therefore, the N and C lobes of ncLf are sufficient to elicit anti-HCV effects in Huh7.5 cells. rcLf and its N lobe displayed similar HCV inhibitory effects to their native counterparts and may constitute an efficient and cost-effective approach for potential clinical applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Inhibitory effects of native and recombinant full-length camel lactoferrin and its N and C lobes on hepatitis C virus infection of Huh7.5 cells

Liao

El-Fakkarany

Lönnerdal

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…It modulates the inflammatory response [10]. Lf has the ability to change in immunity level (e.g., blood phagocytic activities, serum IL-18, interferon) and disease resistance (e.g., hepatitis C virus, influenza virus) in fish [11] and humans [12]. Furthermore, Lf has been shown to have inhibitory effects on tumourigenesis [13] and anti-metastatic activity [14].…”

Section: Introductionmentioning

confidence: 99%

Development of New Strategy for Non-Antibiotic Therapy: Bovine Lactoferrin Has a Potent Antimicrobial and Immunomodulator Effects

Hafez¹,

Ismael²,

Mahmoud³

et al. 2013

AID

View full text Add to dashboard Cite

The antibiotic therapy has many problems, such as antibiotics resistance, hypersensitivity, direct toxicity, antibioticinduced immunosuppresion and super-infections. This is highlighting the need for a new strategy for non-antibiotic therapy through the use of novel immunomodulators as naturally released ones (Lactoferrin). The present study investigates the potential of bovine lactoferrin (bLf), isolated from bovine milk whey, to prevent Staphylococcus aureus (S. aureus), Escherichia coli (E. coli), Streptococcus agalactiae (S. agalactiae) and Pseudomonas aeruginosa (P. aerogenosa) growth and then evaluates its immunomodulator effect. First, bLf isolation was attempted from bovine milk whey using a cation exchange chromatography by SP-Sepharose. Second, the antimicrobial activity assays were trailed to study the antimicrobial activity of bLf. Finally, the immune effect of bLf was studied by lymphocyte transformation test. It was found that bLf was separated around molecular weight of 80 kDa and showed significant inhibitory effect against E. coli followed by P. aeruginosa, S. agalactiae and S. aureus. bLf increased lymphocyte transformations mean values in a dose dependant manner. The highest transformations mean value was determined at 50 µg/mL. In conclusion, these results suggest that bLf is a potent natural antimicrobials and immunomodulator agent.

show abstract

“…LF has a number of biological functions, including antimicrobial and immunomodulatory effects in vitro and in vivo (Brock, 1995;Tomita et al, 2002;Vorland, 1999). It has been reported that orally administered bovine LF reduces the number of pathogenic organisms not only in the gastrointestinal tract (Teraguchi et al, 1995;Wada et al, 1999) but also in tissues distant from the gastrointestinal tract in several animal models of infection (Abe et al, 2000;Bhimani et al, 1999;Haversen et al, 2000) and in humans with chronic hepatitis C and tinea pedis (Ishii et al, 2003;Iwasa et al, 2002;Yamauchi et al, 2000). It is known that LF and an LF-derived antimicrobial peptide, lactoferricin B (LFcin B), inhibit in vitro growth of fungi such as Candida albicans (Kuipers et al, 1999;Wakabayashi et al, 1996Wakabayashi et al, , 1998 and Trichophyton mentagrophytes ; it has been shown that orally administered LF shows a host-protective effect against systemic C. albicans infection in mice (Abe et al, 2000) and cutaneous T. mentagrophytes infection in guinea pigs .…”

Section: Introductionmentioning

confidence: 99%

Effect of orally administered bovine lactoferrin on the immune response in the oral candidiasis murine model

Takakura

Wakabayashi

Ishibashi

et al. 2004

Journal of Medical Microbiology

View full text Add to dashboard Cite

Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months

Cited by 61 publications

References 20 publications

Inhibitory effects of native and recombinant full-length camel lactoferrin and its N and C lobes on hepatitis C virus infection of Huh7.5 cells

Inhibitory effects of native and recombinant full-length camel lactoferrin and its N and C lobes on hepatitis C virus infection of Huh7.5 cells

Development of New Strategy for Non-Antibiotic Therapy: Bovine Lactoferrin Has a Potent Antimicrobial and Immunomodulator Effects

Effect of orally administered bovine lactoferrin on the immune response in the oral candidiasis murine model

Contact Info

Product

Resources

About